Background & AimsTo clarify the relationship between metabolic dysfunction-associated fatty liver disease (MAFLD) and chronic kidney disease (CKD). MethodsThe participants were divided into four groups by the presence or absence of fatty liver disease (FLD) and metabolic dysfunction (MD). MAFLD was defined as having both FLD and MD, whereas CKD was defined as estimated glomerular… Continue reading Metabolic associated fatty #liver disease is the risk factor for chronic #kidney disease
Tag: CKD
#Renal hemodynamics across the adult lifespan: Relevance of #flow pulsatility to chronic kidney disease
Elevated renal flow pulsatility may contribute to the pathogenesis of chronic kidney disease (CKD). The purpose of this study was to investigate the associations among age, renal flow pulsatility, and CKD biomarkers in non-CKD adults and CKD patients. MethodsNon-CKD adults (n = 415) and CKD patients (n = 136) aged between 22 and 83 years underwent the renal blood flow… Continue reading #Renal hemodynamics across the adult lifespan: Relevance of #flow pulsatility to chronic kidney disease
Humoral Response to the Pfizer BNT162b2 #Vaccine in Patients Undergoing Maintenance #Hemodialysis
Coronavirus disease 2019 (COVID-19) is associated with higher morbidity and mortality in patients on maintenance hemodialysis. Patients on dialysis tend to have a reduced immune response to infection or vaccination. We aimed to assess, for the first time to the best of our knowledge, the humoral response following vaccination with the BNT162b2 vaccine in patients… Continue reading Humoral Response to the Pfizer BNT162b2 #Vaccine in Patients Undergoing Maintenance #Hemodialysis
Risk for recurrent #cardiovascular disease events among patients with #diabetes and chronic kidney disease
Adults who have experienced multiple cardiovascular disease (CVD) events have a very high risk for additional events. Diabetes and chronic kidney disease (CKD) are each associated with an increased risk for recurrent CVD events following a myocardial infarction (MI). Methods We compared the risk for recurrent CVD events among US adults with health insurance who… Continue reading Risk for recurrent #cardiovascular disease events among patients with #diabetes and chronic kidney disease
Risk Factor Control and #Cardiovascular Event Risk in People With Type 2 #Diabetes in Primary and Secondary Prevention Settings
To examine the association between the degree of risk factor control and cardiovascular disease (CVD) risk in type 2 diabetes and to assess if the presence of cardio-renal disease modifies these relationships. A retrospective cohort study using data from English practices from CPRD GOLD (Clinical Practice Research Datalink) and the SCI-Diabetes dataset (Scottish Care Information-Diabetes),… Continue reading Risk Factor Control and #Cardiovascular Event Risk in People With Type 2 #Diabetes in Primary and Secondary Prevention Settings
The #Kidney Disease: Improving Global Outcomes (KDIGO) 2020 Clinical Practice Guideline for #Diabetes Management in Chronic Kidney Disease (CKD)
Here attached you may find the takeaways of the guidelines for patients and for clinicians. takeaways for patients: https://kdigo.org/wp-content/uploads/2018/03/Top-10-Takeaways-Patients.pdf takeaways for clinicians: https://kdigo.org/wp-content/uploads/2018/03/Top-10-Takeaways-Clinicians.pdf
Low High‐Sensitivity C‐ #Reactive Protein Level in Korean Patients With Chronic #Kidney Disease and Its Predictive Significance for Cardiovascular Events, Mortality, and Adverse Kidney Outcomes: Results From KNOW‐CKD
Inflammation levels are lower in East Asians than in Western people. We studied the association between high‐sensitivity hs‐CRP (C‐reactive protein) and adverse outcomes in Korean patients with chronic kidney disease. Methods and Results We included 2018 participants from the KNOW‐CKD (Korean Cohort Study for Outcome in Patients With Chronic Kidney Disease) between April 2011 and… Continue reading Low High‐Sensitivity C‐ #Reactive Protein Level in Korean Patients With Chronic #Kidney Disease and Its Predictive Significance for Cardiovascular Events, Mortality, and Adverse Kidney Outcomes: Results From KNOW‐CKD
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, its long-term effects on kidney and cardiovascular outcomes are unknown. ..During a median follow-up of 2.6 years, a primary outcome event occurred in 504 of 2833 patients (17.8%) in the finerenone… Continue reading Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
#Dapagliflozin in Patients with Chronic #Kidney Disease
Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.. ..The independent data monitoring committee recommended stopping the trial because of efficacy. Over a median of 2.4 years, a primary outcome… Continue reading #Dapagliflozin in Patients with Chronic #Kidney Disease
2 Medical News 